Hyperactive Delirium with Severe Agitation

Hyperactive delirium with severe agitation is acute disorientation that shows up as aggressive words or actions. The ACEP 2021 task force calls it an acute, life-threatening condition that needs emergency treatment, and it uses this descriptive term instead of excited delirium. It is a syndrome with many possible causes. Treatment starts before the cause is known.

Nobody has pinned down a single mechanism. Catecholamine and dopamine excess is implicated. It goes with hyperthermia, tachycardia, metabolic acidosis and muscle breakdown. Struggling and physical restraint add to all of it.

• Common triggers: stimulants such as cocaine and methamphetamine, alcohol, benzodiazepine, GHB or barbiturate withdrawal, and psychiatric illness such as psychosis, mania or schizophrenia
• Metabolic and structural causes: hypoglycemia, hypoxia, acidosis, dysrhythmia, stroke, intracranial bleeding and infection
• Clinical course: hyperthermia, rhabdomyolysis and acidosis can progress quickly. The task force describes rapid physiologic deterioration and death, especially with comorbidity

Typical Presentation

• Mental status: you'll see disorientation with aggression, hallucinations or psychosis. De-escalation alone is often not enough, says the ACEP 2021 task force.
• Autonomic signs: tachycardia, tachypnea, hyperthermia, hypertension, diaphoresis and mydriasis
• Exam findings: tremor, myoclonus, clonus, lower-extremity rigidity and repetitive behavior

Red Flags

• Temperature high or rising, or hot, sweating skin
• Low fingerstick glucose at any level below the local protocol threshold
• Falling SpO₂ or respiratory rate, shallow breathing or apnea after sedation
• Hypotension, or sustained hypertension with tachycardia
• Focal neurologic deficit, head injury or signs of an injury from struggle or restraint

Run these checks while you manage agitation that endangers the patient or crew. A glucose reading settles the hypoglycemia question within minutes, one way or the other. The task force adds that hypoglycemia cannot be diagnosed at autopsy.

• Hypoglycemia: low fingerstick glucose. A fast, complete response to glucose tells it apart from psychiatric agitation
• Sympathomimetic toxicity: tachycardia, hyperthermia, mydriasis, tremor and hyperattentiveness after stimulant use
• Alcohol, benzodiazepine, GHB or barbiturate withdrawal: the body's own sympathomimetic state. An abrupt stop in the history points here
• Stroke, intracranial bleeding or mass lesion: focal deficit, headache or vomiting. Imaging settles it
• Serotonin syndrome and neuroleptic malignant syndrome: clonus after serotonergic drugs points one way. Rigidity with autonomic instability after antipsychotic exposure points the other
• Primary psychiatric illness: psychosis, mania or schizophrenia with an intact sensorium. These patients may respond to de-escalation

1. Scene safety first: call for law enforcement support when the scene is unsafe; the 2024 NAEMSP, IAFC and IACP consensus describes shared roles.
2. Verbal de-escalation: a calm, single speaker, space and simple choices. Attempt it first, in parallel with preparation for sedation when the patient is dangerous.
3. Protect the crew and patient: remove objects that can cause injury; keep a clear exit path for the crew.
4. Restraint is temporizing only: use the least restraint needed for the shortest time, never as a substitute for sedation. Never place the patient prone; keep them upright or on the side and watch the airway.
5. Check glucose and temperature and treat per protocol. Give oxygen if SpO₂ is low.
6. Call for ALS early, and do not delay transport for sedation that is still being prepared.

Restraint without sedation is tied to a much higher risk of injury and death in this population. The exposure history changes the plan. See Toxidromes.

Doses vary by protocol; follow local protocols and medical direction. Medical direction should be reachable by radio or phone for every sedation decision.

• Indication: parenteral sedation comes in when de-escalation fails, or when the agitation endangers the patient or crew (Paramedic/RN/CCT).
• Agent choice: there is no single winner. The 2021 ACEP task force could not name one. Ketamine, droperidol, olanzapine and midazolam given IM carry the strongest support, so the protocol's pick is the one you use.

• Ketamine (Paramedic/RN/CCT): give 4 mg/kg IM once, using the weight the protocol specifies. Plenty of protocols set a fixed or maximum single dose. No guideline sets an absolute mg cap, so follow local protocol. Dissociation and emergence reactions are expected. Laryngospasm and hypersalivation can require intubation, so keep airway equipment, suction and capnography within reach. Repeat only with medical direction. See Ketamine.
• Droperidol: off-label, ACEP uses 5–10 mg IM or IV for agitation. The label's first maximum is 2.5 mg IM or slow IV, with 1.25 mg added doses. A prolonged QTc rules it out: known or suspected QT prolongation, congenital long QT, or a QTc above 440 ms (men) or 450 ms (women). Use extra care with bradycardia, hypokalemia, hypomagnesemia, heart failure, other QT-prolonging drugs (including benzodiazepines), alcohol abuse and age over 65. Continue ECG monitoring for 2–3 hours after dosing (label). With no 12-lead ECG available, follow the local protocol, which may choose another agent. See Droperidol.
• Olanzapine: 10 mg IM is the label's recommended adult dose. Drop to 5 mg for older patients, and to 2.5 mg for debilitated or hypotension-prone patients (label range 2.5–10 mg). Before any repeat, check orthostatic BP. The label has not evaluated doses more often than 2 hours after the first, or 4 hours after the second, or totals above 30 mg/day. See Olanzapine.
• Midazolam: When the protocol reaches for a benzodiazepine, it's 5 mg IM. ACEP 2021 favors midazolam over lorazepam for speed. Over 60, debilitated, or on opioids or other CNS depressants? The midazolam label calls for lower doses. Protocol sets how much lower. See Midazolam.
• Haloperidol and lorazepam: haloperidol 5–10 mg IM, with or without a benzodiazepine, depends on the protocol. Per ACEP 2021, it works more slowly than droperidol, olanzapine or midazolam, about 20–60 minutes. Every study ACEP 2021 reviewed put droperidol equal to or ahead of haloperidol. Lorazepam was slower than midazolam. See Haloperidol and Lorazepam.

• Monitoring after any sedative: continuous SpO₂, waveform capnography and ECG; reassess sedation, respiratory rate and vital signs 10–20 minutes after each dose and before any repeat, per protocol.
• Escalate: if sedation fails, or airway or breathing is at risk, call medical direction and prepare an advanced airway. See RSI.

• ED agent choice: secondary literature cites the ACEP 2024 policy as favoring droperidol or an atypical antipsychotic, alone or with midazolam. The full text was not reviewed for this page. In an ED randomized trial of IV agents, midazolam 5 mg with droperidol 5 mg sedated significantly more patients at 10 minutes than droperidol 10 mg or olanzapine 10 mg alone. A separate IM study cited in ACEP 2021 found no advantage for the combination over either drug alone. Most evidence is IV. The IM combination is less studied.
• Diagnostics: point-of-care glucose, temperature, ECG, CK, electrolytes, creatinine and acid-base status. CT head for focal signs or head injury. Expect rhabdomyolysis, electrolyte disturbance and kidney injury after prolonged struggle and restraint.
• Airway: ketamine can cause laryngospasm and hypersalivation that need intubation. Every sedated patient who fails to improve needs an airway plan. See RSI.
• ICU sedation: for ventilated adults, the 2025 SCCM PADIS focused update conditionally recommends dexmedetomidine over propofol. It gives no recommendation for antipsychotics to treat delirium. See Dexmedetomidine and Analgosedation.
• Medical direction: the ACEP 2021 task force recommends a physician board-certified in emergency or EMS medicine lead treatment.

• Destination: transport to an emergency department with monitoring and airway capability. A focal deficit goes to a stroke center. A major injury goes to a trauma center.
• Monitoring in transit: continuous SpO₂, waveform EtCO₂ and ECG; check temperature and glucose again; watch for a drop in breathing after sedation; continue monitoring until the patient is awake and cooperative, per local protocol.
• Position: not prone at any point in transport. Keep the patient upright or on the side, with restraints reviewed at each reassessment and released as soon as the patient is safe.
• Handoff: name, time and dose of each drug, weight used for mg/kg dosing, cumulative benzodiazepine total, restraint start time, glucose, temperature, SpO₂ and EtCO₂ trend, and response.
• Equipment: suction, airway kit, capnography, and dose calculator for the weight-based drug; see Capnography.
• Shared response: coordinate law enforcement and EMS roles, per the 2024 NAEMSP, IAFC and IACP consensus on collaboration.

• Pediatrics: doses are weight-based, and most agents are off-label for agitation. BETA 2019 gives weight-band doses for antipsychotics and benzodiazepines. It also says olanzapine should not be given with or within 1 hour of a benzodiazepine, because of respiratory suppression. Use the pediatric columns on each medication page and Weight-Based Dosing. On the olanzapine label (all forms), safety and effectiveness are not established under 13 years. For age-based limits, see Vital Signs.
• Pregnancy: an agitated pregnant patient still needs a search for eclampsia, hypoglycemia and hypoxia. See Preeclampsia and Eclampsia. Data on these sedatives in pregnancy are limited. Don't withhold treatment that an emergency requires. Decide with medical direction, and record the risk-benefit reasoning.
• Older Adults: a 2025 geriatric emergency systematic review advises avoiding benzodiazepines where possible. It favors oral medications and the lowest effective dose. For IM olanzapine, use 5 mg for older patients and 2.5 mg for debilitated or hypotension-prone patients (label), with orthostatic BP checks before repeat doses. The midazolam label calls for lower doses in patients over 60, and in those on opioids or other CNS depressants. The olanzapine label carries a boxed warning on dementia-related psychosis. A 2026 analysis of state EMS protocols found only 11 of 33 addressed older adults. None changed physical restraint criteria for them.
• Renal Impairment: no specific adjustment is established for these agents in this pathway. Watch for kidney injury from rhabdomyolysis, and dose by response.
• Hepatic Impairment: the olanzapine label notes clearance drops in hepatic impairment. Titrate to response and check each medication page.
• Obesity: ketamine and midazolam are dosed by weight. Use the weight the protocol specifies, and record it in the handoff.

• Error: restraint without sedation, or a prone position. ACEP 2021 puts the odds ratio for fatality at 7.4 with restraint without sedation. Sedate. Position upright or on the side. Release restraint once safe.
• Error: anchoring on a psychiatric cause. Glucose, temperature, SpO₂ and focal signs come first, before you attribute the behavior to psychiatric illness.
• Error: stacking benzodiazepine doses across home, EMS and ED. Add up every dose already given before the next one.
• Error: repeating olanzapine too soon or above 30 mg/day. Check orthostatic BP first. The label has not evaluated doses more often than 2 hours after the first or 4 hours after the second, or totals above 30 mg/day.
• Error: giving droperidol without a 12-lead ECG or with a prolonged QTc. The label requires the ECG. The ACEP 2021 task force calls that monitoring impractical, so follow the label and local protocol.
• Error: ketamine dose errors come from several concentrations and a weight-based dose. Confirm the mg, the mL and the weight used before each dose.